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The effect of one-month amlodipine treatment
on plasma endothelin-1 concentration
in hypertensive patients
Wpływ jednomiesięcznego podawania amlodipiny na osoczowe stężenie endoteliny-1
(ET-1) u pacjentów z nadciśnieniem tętniczym
Streszczenie
Wstęp Ochrona śródbłonka naczyniowego i mięśni
gładkich naczyń w następstwie zastosowania anta-
gonistów wapnia jest związana z wieloma mechani-
zmami, spośród których oddziaływanie na endoteli-
nę-1 (najsilniej działającą kurcząco na naczynia sub-
stancję endogenną) wydaje się niesłychanie istotne.
Celem pracy była ocena wpływu amlodipiny (anta-
gonisty wapnia, pochodnej dihydropirydyny III ge-
neracji) na osoczowe stężenie endoteliny-1 (ET-1)
oraz stężenie aldosteronu (Ald) w surowicy chorych
z pierwotnym nadciśnieniem tętniczym (EH).
Materiał i metody Grupa badana liczyła 39 pacjentów
(18 kobiet i 21 mężczyzn) z EH w stadium I wg klasy-
fikacji WHO. Do badań nie zakwalifikowano chorych
z wtórnymi postaciami nadciśnienia tętniczego oraz
chorobami mogącymi wpływać na stężenie ET-1.
U wszystkich badanych oceniano następujące parametry:
— SBP — ciśnienie tętnicze skurczowe;
— DBP — ciśnienie tętnicze rozkurczowe;
— ET-1 — stężenie ET-1 w osoczu;
— Ald — stężenie aldosteronu w surowicy;
przed (I badanie) i po 30 dniach podawania amlodi-
piny w dawce 5 mg/dobę (II badanie).
Wyniki Leczenie amlodipiną przez 30 dni (5 mg/d.)
spowodowało:
1. Istotne obniżenie SBP (średnia ± SD: I badanie:
160,17 ± 9,76 v. II badanie: 131,78 ± 11,83 mm Hg,
p = 0,0000001).
2. Istotne obniżenie DBP (średnia ± SD: I badanie:
93,58 ± 7,71 v. II badanie: 74,17 ± 10,03 mm Hg,
p = 0,0000001).
3. Nieistotne statystycznie obniżenie ET-1 (media-
na ± S: I badanie: 83,3 ± 23,9 v. II badanie: 78,7 ±
20,85 pg/ml, p = 0,102).
4. Nieistotne statystycznie podwyższenie Ald (me-
diana ± S: I badanie: 125,9 ± 66,53 v. II badanie:
158,49 ± 76,15 pg/ml, p = 0,52).
Wnioski Terapia amlodipiną przez 30 dni w dawce
5 mg/dobę u pacjentów z EH prowadziła do nie-
istotnego statystycznie obniżenia stężenia ET-1, co
może mieć znaczenie dla zastosowania tego leku
w codziennej praktyce. Jednak ograniczeniem opisy-
wanego badania była stosunkowo niewielka liczeb-
ność grupy badanej (39 chorych), co przemawia za
potrzebą poszerzenia badań.
słowa kluczowe: endotelina-1, amlodipina, pierwotne
nadciśnienie tętnicze, antagoniści wapnia
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Introduction
Endothelial cells are located between circulating
blood and vascular smooth muscle. Nowadays, the-
se cells are regarded as an endocrine organ, rele-
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asing numerous vasodilatative and vasoconstrictive
substances. Although among them prostacyclin,
bradykinin, nitric oxide and endothelium-derived
hyperpolarizing factors play a vasodilatative role,
angiotensin II and endothelin-1 are the most im-
portant vasoconstrictors. Moreover, the last mentio-
ned also exerts mitogenic, prothrombotic and in-
flammatory action.
Calcium antagonists (Ca-A), especially 1.4-dihy-
dropiridine, have been widely used for the treatment
of many cardiological disorders, not only because of
their haemodynamic and electrophysiological pro-
perties, but also because of those concerning vascu-
lar protection. These last effects are especially im-
portant in the face of the dysfunction of the endothe-
lium, commonly observed in most internal disorders,
cardiovascular, in particular.
Endothelium and smooth muscle protection after
Ca-A are markedly related to several mechanisms,
among which the most important are:
1. Vasorelaxation modulated by the improvement
of endothelial nitric oxide (NO) availability. This
effect may be partially associated with the decrease of
angiotensin II, since this substance stimulates
NAD(P)H oxidase-responsible for the formation of
superoxide, which inactivates NO. Also kinins (what
has been proved in another model with amlodipine
treatment) may release NO from microvessels [1].
2. Calcium antagonist activity. In fact, this me-
chanism is very unlikely since endothelial cells do
not express voltage-operated calcium channels. On
the other hand, however, it should be recognized,
that these drugs counteract angiotensin II and ET-1
at the level of vascular smooth muscle by reducing
the inflow of calcium ions (Ca2+) [2].
3. Antioxidant effects and protection against free
radical injury. It has been noted that nifedipine de-
creases circulating parameters of oxidative stress and
prevents the effect of the antioxidant vitamin C [3, 4].
Moreover, amlodipine has preserved plasma total su-
peroxide dismutase (SOD) activity in animal models
[5]. However, even the strongest up-regulation of
SOD activity was observed after treatment with pra-
nidipine [6].
4. Anti-atherogenic reaction. This property has
been described in many experimental and clinical
studies, and, what is very interesting, has been obser-
ved independently of blood pressure reduction or
plasma lipids changes [7].
5. Probably anti-endothelin activity. Endothelin-1
(ET-1) is a 21-amino-acid peptide synthesized and
released primarily in the vascular endothelium, and
is regarded as the most powerful endogenous vaso-
constrictor. Since its first description [8] it has been
the subject of intense research which has revealed
also mitogenic property of ET-1. Many physical and
chemical stimulatory factors of ET-1 synthesis have
been described, among them: increase of shear stress,
adrenaline, angiotensin II, vasopressin, transforming
growth factor b, interleukin-1 (IL-1), IL-2, IL-3,
thrombin and insulin. Some substances may inhibit
ET-1 production: nitric oxide, bradykinin, cGMP,
prostacyclin, natriuretic peptides and heparin [9].
Moreover, the role of ET-1 in the pathogenesis of
a variety of cardiovascular and non-cardiovascular
diseases has been established. This peptide has been
especially recognized as an important element in the
pathogenesis of arterial hypertension. Since then, the
influence of various types of antihypertensive drugs
on ET-1 synthesis and effects have been assessed in
many experimental and clinical studies.
Mechanisms involved in the interaction between Ca-A
and ET-1 have been also described. They include:
Interaction through voltage-operated Ca2+ channels
It has been observed that ET receptors on the vascu-
lar smooth muscle in the coronary artery are linked to
voltage-operated Ca2+ channels via G proteins [10].
ET(A) receptor couples to Gq/11 protein leading
to transduction of receptor signals, playing also a role
in Ca2+ mobilization. Despite the evidence observed
in many studies that ET-1 receptor stimulation via
the above-mentioned Gq/11 protein induces an in-
crease in intracellular Ca2+, this has not been proved
by all researchers [11].
Influence of sarcoplasmatic-endoplasmatic reticu-
lum Ca2+-ATPase on the ability of an ET receptor
antagonist to inhibit the ET-1 constriction was as-
sessed by Tosun et al. [12]. This study indicated that
lowered sarcoplasmatic-endoplasmatic reticulum
Ca2+-ATPase activity decreases the ability of an ET
receptor antagonist to inhibit the ET-A receptor,
which may be related to the opening of store-opera-
ted channels leading to the enhancement of the in-
ternalization of the ET-A receptor.
Phospholipase C and diacylglycerol
Activation of ET receptors releases the cascade of
phospholipase C and diacylglycerol with increased
formation of inositol triphosphate, which releases
Ca2+ from the sarcoplasmatic reticulum leading to
increased cytosolic Ca2+ [13].
Ca2+-activated K+ channels
Activation of Ca2+-activated K+ channels with the
high degree of conductance by ET-1 provoked a ca-
pacitative Ca2+ influx which induced endothelial cell
proliferation [14].
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Inhibition of sympathetic system
Despite the widely-described activation of the
sympathetic nervous system observed after short-ac-
ting dihydropyridines, adverse effects have been also
presented in some studies. Vasoconstriction caused
by phenylephrine [15, 16] or other a-agonist [17]
was reduced by nifedipine [18], diltiazem [15], am-
lodipine [16], verapamil [17] and nitrendipine [17].
Influence on NO availability
The fact that NO is an inhibitor of ET-1 synthe-
sis, and widely mentioned in many studies, may be
partially responsible for interaction between Ca-A
and ET-1.
As has already been described nifedipine incre-
ased NO bioavailability in essential hypertension,
probably partially due to the antioxidant efficacy
of this drug [3, 4]. Therefore, the vasodilatative
effect observed, especially after dihydropyridines,
is inhibited in the presence of NO-synthase inhi-
bitors [19].
Objectives
The aim of this study was to investigate the in-
fluence of amlodipine (dihydropyridine calcium
channel blocker, III generation) on plasma endo-
thelin-1 (ET-1) and serum aldosterone (Ald) con-
centration in patients with essential arterial hyper-
tension (EH).
Material and methods
The study population included 39 patients (18 wo-
men and 21 men) with EH in stage I according to
WHO classification. Selection criteria excluded pa-
tients with a secondary form of arterial hypertension
and any additional diseases influencing ET-1 plas-
ma concentration, like diabetes mellitus, angina
pectoris, autoimmune disorders and renal diseases
with impairment of renal function. The mean systo-
lic blood pressure (SBP) was 160.17 ± 9.76, the mean
diastolic blood pressure (DBP) was 93.58 ± 7.71. In
the fundoscopic findings, grade I was observed in
7 patients, s grade I/II — in 16 ones and grade II in
16 individuals. The average age of the study popula-
tion was 59.89 ± 9.13 years.
Clinical and biochemical characteristics of hyper-
tensive patients included in the study before the tre-
atment with amlodipine (tab. I).
In all of the patients the following parameters
were assessed:
— SBP — systolic blood pressure;
— DBP — diastolic blood pressure;
— ET-1 — endothelin-1 plasma concentration;
— Ald — aldosterone serum concentration;
before (I study) and after 30-day treatment with am-
lodipine in dose 5 mg/day (II study).
Patients were asked to fast overnight (from
food, caffeine, tobacco, alcohol and drugs). In the
majority of cases the patients did not undergo
anti-hypertensive treatment before investigation,
while in some situations amlodipine was added
to the treatment which did not influence ET-1
concentration. Blood samples were collected du-
ring rest (lasting for at least 2 hours), in a lying
position.
Blood samples for the determination of plasma
ET-1 were drawn into prechilled EDTA tubes on
ice, centrifuged at 2500 g for 10 min. The plasma
was frozen at –70oC and stored for 2–7 weeks. Pla-
sma levels of ET-1 and serum Ald concentration
were estimated with radioimmunoassay (ET-1:
DRG International Inc., USA; Ald: Immunotech SA,
France).
Statistical analysis
Wilcoxon’s test was used to check the statistical
significance of the difference between nonparame-
tric values. Correlations between parameters were as-
sessed by using Spearman’s tests. Results were
expressed as mean ± SD, apart from ET-1 and Ald
which were expressed as median ±S. Differences
were considered statistically significant at a value of
p < 0.05.
Table I. Evaluated parameters
Tabela I. Charakterystyka badanych
Gender (F/M) 18/21
Age (years) 59.89 ± 9.13
SBP [mm Hg] 160.17 ± 9.76
DBP[mm Hg] 93.58 ± 7.71
Glucose [mmol/l] 5.08 ± 0.49
Creatinine [mmol/l] 79.41 ± 14.43
Urea [mmol/l] 5.81 ± 1.33
K+ [mmol/l] 4.46 ± 0.27
Total cholesterol [mmol/l] 5.15 ± 1.21
LDL [mmol/l] 3.01 ± 1.02
ET-1 (plasma) [pg/ml] 83.3 ± 23.9
Ald (serum) [pg/ml] 125.9 ± 66.53
SBP — systolic blood pressure, DBP — diastolic blood pressure, K+ — serum potassium
concentration, LDL — serum low-density lipoprotein concentration, ET-1 — plasma endothe-
lin-1 concentration, Ald — serum aldosterone concentration
Data are presented as mean ± SD, except ET-1, aldosterone concentration presented as
median ± S
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Results
30-day treatment with amlodipine (5 mg/day) led to:
— a significant decrease of SBP (Mean ± SD: I
study: 160.17 ± 9.76 vs II study: 131.78 ± 11.83 mm Hg,
p = 0.0000001);
— a significant decrease of DBP (Mean ± SD: I
study: 93.58 ± 7.71 vs II study: 74.17 ± 10.03 mm Hg,
p = 0.0000001);
— a non-significant decrease of ET-1 conc. (Me-
dian ± S I study: 83.3 ± 23.9 vs II study: 78.7 ±
20.85 pg/ml, p = 0.102) (fig. 1);
— a non-significant increase of Ald conc. (Me-
dian ± S I study: 125.9 ± 66.53 vs II study: 158.49 ±
76.15 pg/ml, p = 0.52) (fig. 2).
We also observed a correlation between Ald conc.
(before treatment) and SBP (before treatment), p =
0.042 (fig. 3) and a correlation between changes in
ET-1 conc. and changes in DBP, p = 0.026 (fig. 4).
Discussion
The influence of calcium antagonists on endothe-
lin-1 (ET-1) concentration have been assessed in se-
veral studies. In some research, a decreased, unchan-
ged, or even increased ET-1 concentrations after Ca-A
therapy have been noted.
In a very interesting study by Krenek et al. [20] the
effect of long-term treatment with lacidipine in salt-
Figure 1. ET-1 plasma conc. in EH patients before (I study) and
after (II study) 30-day therapy with amlodipine 5 mg/day
Rycina 1. Stężenie ET-1 w osoczu pacjentów z EH przed (I bada-
nie) i po (II badanie) 30-dniowej terapii 5 mg amlodipiny na dobę
Figure 2. Ald conc. in EH patients before (I study) and after (II
study) 30-day therapy with amlodipine 5 mg/day
Rycina 2. Stężenie Ald w surowicy pacjentów z EH przed (I bada-
nie) i po (II badanie) 30-dniowej terapii 5 mg amlodipiny na dobę
Figure 3. Correlation between Ald conc. (before treatment) and SBP (before treatment), p = 0.042
Rycina 3. Korelacja między stężeniem Ald (przed leczeniem) a SBP (przed leczeniem), p = 0,042
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loaded stroke-prone hypertensive rats on endothelium
dependent vasorelaxation was assessed. High-sodium
diet (1% NaCl in drinking water) induced elevated
blood pressure and aortic weight, wall thickness, and
increased plasma renin activity PRA (from 5.3 ± 0.8
to 13.0 ± 2.8 ng/ml/h) whereas the parameters of en-
dothelium dependent vasodilatation was significantly
decreased. Also preproendothelin-1 levels were eleva-
ted twofold (p < 0.01). Six weeks of treatment with
lacidipine at a dose of 1 mg/kg/day prevented these
structural and functional aortal abnormalities, among
which the increase of preproendothelin-1 mRNA was
also completely prevented. The explanations for this
were various. The antioxidant efficacy of calcium an-
tagonists, with secondarily increased bioavailability of
NO was taken into account as a possible reason. De-
creased PRA after lacidipine, with a secondary decre-
ase of angiotensin II production might also have con-
tributed to the prevention of preproendothelin-1
over-expression.
Moreover, in a study by Godfraind et al. [21] laci-
dipine administered in spontaneous hypertensive
stroke-prone rats reduced endothelin production pre-
viously enhanced by a high-salt diet.
Yang et al. reported that pranidipine suppressed
basal and thrombin-stimulated ET-1 production in
endothelial cells. This drug also enhanced the vaso-
dilatatory effect of NO, by releasing NO from endo-
thelial cells and by increasing of cGMP accumula-
tion in vascular smooth muscle cells [6].
Positive effects have also been noted after five we-
eks of administering benidipine in subdepressor do-
ses — 1 mg/kg/day in salt-sensitive hypertensive rats,
and resulted in a significant improvement of my-
ocardial remodeling and left ventricular hypertrophy.
These beneficial effects might be partially associated
with decreased ET-1 expression in the left ventricle
observed after benidipine treatment [22].
On the other hand, Hishikawa et al. reported si-
gnificant increase of ET-1 release from cultured hu-
man umbilical vein endothelial cells provoked by
pressure, but this process was not affected by nifedi-
pine administration (5 µmol/l) [23].
In a study by Åsberg et al., the effects of long-term
treatment with slow-release nifedipine (30–60 mg
s.i.d.) or lisinopril (10–20 mg s.i.d.) on microvascu-
lar function in hypertensive renal transplant reci-
pients were assessed. In fact, more beneficial effects
were observed after lisinopril than after nifedipine
treatment. Whereas in the nifedipine group plasma
ET-1 concentrations were 0.44 ± 0.19 fmol/ml, in
the lisinopril group they were significantly lower, and
reached values 0.34 ± 0.10 fmol/ml, p = 0.048. Mo-
reover, in controls ET-1 concentrations were 0.29 ±
0.09 fmol/ml. Such results may indicate a endothe-
lial protective effect of lisinopril only. According to
these authors, the higher plasma ET-1 level obse-
rved in the calcium antagonist group may be associa-
ted with decreased NO activity (inhibitor of ET-1
synthesis), as a result of endothelial dysfunction per
se, or decreased NO bioavailability caused by higher
angiotensin II concentration in the Ca-A group than
in patients treated with an angiotensin-converting
enzyme inhibitor [24].
Many studies have revealed that dihydropyridine
Ca-A, especially the administration of short-acting
drugs, and in some observations even after the chro-
nic administration of those which are long-acting,
have led to the activation of the sympathetic nervous
and renin-angiotensin systems [25, 26]. It has been
also widely described that angiotensin II and norepi-
nephrine may activate ET-1 synthesis and could pro-
Figure 4. Correlation between changes of ET-1 conc. and changes of DBP, p = 0.026
Rycina 4. Korelacja między zmianami stężenia ET-1 a zmianami DBP, p = 0,026
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voke over-expression of growth factors [8]. Such neu-
rohormonal changes observed after Ca-A might li-
mit their antihypertrophic effects. This theory has
been proved in an experimental setting when high-
dose amlodipine (20 mg/kg/day), previously repor-
ted to stimulate the renin-angiotensin and sympa-
thetic nervous systems, provoked over-expression of
preproendothelin-1 mRNA levels in the ventricles
and aorta in Sprague-Dawley rats. This result was
linked to higher relative left ventricular mass, obse-
rved after long-term administration (5 weeks), and
higher relative right ventricular mass noted both after
long- and short-term treatment (5 days) with amlo-
dipine [27].
Regarding these data, we decided to assess the in-
fluence of amlodipine in such a dose (5 mg/day) that
is not expected to influence neurohormonal balance.
In fact, our results showed no effects on PRA and
Ald concentrations after one month of amlodipine
treatment, and as a consequence of these facts no
influence of the renin-angiotensin-aldosteron system
on ET-1 concentration should be mentioned.
It is also noteworthy, that as in previously descri-
bed studies concerning the influence of Ca-A on ET-1
concentration, also the effect of amlodipine on ET-1
is unclear. Treatment with amlodipine may lead to
an increase of ET-1 values, as in a study by Inigo et
al. [28], where this drug, when administered to renal
transplant recipients caused significantly higher ET-1
concentration compared with a group of patients un-
dergoing losartan treatment. On the other hand,
some studies have not revealed any influence of am-
lodipine on ET-1. Such results were observed for
example in a study by Salomon et al. [29], where one
month of treatment with amlodipine (5–10 mg/day)
in patients with congestive heart failure (NYHA II
and III) did not change plasma ET-1 concentration
despite the improvement of circulatory efficiency as-
sessed according to the NYHA classification. In the
same way, Chen et al. [30] also demonstrated that
amlodipine monotherapy in spontaneous hyperten-
sive rats had no detectable effects on intrarenal endo-
thelin concentration. These results are in agreement
with findings of our research. Despite the fact that
we observed a tendency toward decreased ET-1 con-
centration after 30-day treatment with 5 mg of amlo-
dipine in hypertensive patients, this effect was not
statistically significant. However, regarding the abo-
ve-mentioned study by Inigo et al., it is very impor-
tant to notice that amlodipine did not increase ET-1
concentration in our group.
It should be also mentioned here, that in an expe-
rimental model of congestive heart failure provoked
by doxorubicine in rats and mice, two weeks of amlo-
dipine treatment (at a dose of 0.07 mg/day) reversed
a large increase in endothelin-1 concentration [31].
There is also growing evidence that Ca-A may
influence ET-1 effects both in humans and in ani-
mals. In a study by Kiowski et al. [32], a low-dose of
ET-1 infusion (0.5 ng/min) in healthy, normotensi-
ve volunteers resulted in a significant increase in fo-
rearm blood flow, while high-doses of peptide (25 or
50 ng/min) led to vasoconstriction. Although treat-
ment with Ca-A- nifedipine in doses of 0.25; 0.5 or
3 µg/min per 100 ml forearm tissue, resulted in a dose-
dependent increase of forearm blood flow (p < 0.05),
not only when nifedipine was administered alone,
such results were also observed after co-infusion of
both ET-1 and nifedipine. In comparison, such ce-
asing of ET-1 vasoconstrictor activity was also noted
after verapamil administration in a dose of 80 µg/
/min per 100 ml forearm tissue. In conclusion, both
verapamil (non-dihydropiridine Ca-A) and nifedipi-
ne (dihydropiridine Ca-A) prevented the ET-1 in-
duced decrease in forearm blood flow.
In another study Rabelink et al., the effects of ET-1
infusion on renal function in humans were asses-
sed. A twofold increase in plasma ET-1 levels did
not influence renal and systemic hemodynamics,
while sodium excretion was significantly blunted.
Whereas ET-1 infusion resulting in a threefold-in-
creased peptide concentration in plasma significan-
tly decreased renal plasma flow, the glomerular fil-
tration rate, increased filtration fraction, renal vascu-
lar resistance, as well as sodium retention. Pretreat-
ment with nifedipine at a dose which did not influ-
ence blood pressure (0.01 mg/kg/hr) attenuated re-
nal vascular resistance and the antinatriuretic effects
of ET-1 [33].
Moreover, a study by Kaasjager et al. [34] was
designed to assess whether ET-induced renal vaso-
constriction in humans may be stopped by nifedipi-
ne. The administration of the drug (priming dose
0.015 mg/kg, maintenance infusion 0.015 mg/kg/hr)
on a top of ET-1 infusion reversed all the changes
caused by ET-1, such as increased renal vascular re-
sistance, sodium retention, decreased lithium cle-
arance. No effect on the increased filtration fraction
was observed, suggesting that influence of ET-1 and
nifedipine on renal microcirculation did not overlap
completely.
Recently the chronic effects of the nifedipine ga-
strointestinal therapeutic system (GITS) on vasocon-
striction caused by ET-1 infusion in normotensive
patients, and in those with essential hypertension,
has been tested. ET-1 at a dose of 0.5 µg/100 ml of
forearm tissue per minute caused a slight vasodilata-
tion in normotensive but not in hypertensive pa-
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tients. Higher doses of peptide (25; 50 µg/100 ml)
led to dose-dependent vasoconstriction in both gro-
ups, and there were no differences between hyper-
tensive normo- and hypercholesterolemic patients.
Long-term treatment (24 weeks) with nifedipine
GITS (30–60 mg/day) in hypertensive subjects dimi-
nished these consequences of ET-1 [18].
Ca-A may be also used during cyclosporine admi-
nistration in transplant recipients. It has been reco-
gnized that renal dysfunction induced by cyclospori-
ne A is associated with renal ET receptor up-regula-
tion and increased urinary ET excretion. Moreover,
treatment with nifedipine in rats during cyclosporine
A administration had the ability to attenuate urinary
ET excretion, without any influence on ET recep-
tors [35].
The results of the above-presented research are
especially interesting because of disagreement betwe-
en the widely-described positive influence of Ca-A
on ET-1 effects (the stopping of many changes cau-
sed by ET-1) and the poorly-documented effects of
this group of drugs on ET-1 concentration (also ob-
served in our study). It should be taken into conside-
ration that the ET system is an autocrine/paracrine
system and plasma concentration may reflect a “spill
over” from local vascular production rather than true
local activity.
Conclusion
In conclusion, 30-day treatment of essential hy-
pertensive patients with amlodipine at a dose of
5 mg/day induced a non-significant decrease of ET-1
concentration which may be important for the thera-
peutic use of amlodipine in everyday practice. Ho-
wever, it should be also noted that our data were
collected from a relatively small group of patients
(39), and probably need to be confirmed in larger
population sample.
Summary
Background Endothelium and smooth muscle protection
after calcium antagonists (Ca-A) are markedly related to se-
veral mechanisms, among which the influence on endothelin-
1 (a substance regarded as the most powerful endogenous
vasoconstrictor) seem to be very important.
The aim of this study was to investigate the influence of
amlodipine (dihydropyridine Ca-A, III generation) on plasma
endothelin-1 (ET-1) and serum aldosterone (Ald) concentra-
tion in patients with essential arterial hypertension (EH).
Material and methods The study population included 39
patients (18 women and 21 men) with EH in stage I ac-
cording to WHO classification. Selection criteria excluded
patients with a secondary form of arterial hypertension and
any additional diseases influencing ET-1 plasma concen-
tration.
In all of the patients the following parameters were as-
sessed:
— SBP — systolic blood pressure;
— DBP — diastolic blood pressure;
— ET-1 — endothelin-1 plasma concentration;
— Ald — aldosterone serum concentration;
before (I study) and after 30-day treatment with amlodipine
in dose 5 mg/day (II study).
Results 30-day treatment with amlodipine (5 mg/day) led to:
1. Significant decrease of SBP (Mean ± SD: I study: 160.17
± 9.76 vs II study: 131.78 ± 11.83 mm Hg, p =
0.0000001).
2. Significant decrease of DBP (Mean ± SD: I study: 93.58
± 7.71 vs II study: 74.17 ± 10.03 mm Hg, p = 0.0000001).
3. Non-significant decrease of ET-1 conc. (Median ± S I
study: 83.3 ± 23.9 vs II study: 78.7 ± 20.85 pg/ml, p =
= 0.102).
4. Non-significant increase of Ald conc. (Median ± S I study:
125.9 ± 66.53 vs II study: 158.49 ± 76.15 pg/ml, p = 0.52).
Conclusion 30-day treatment of essential hypertensive pa-
tients with amlodipine in dose 5 mg/day induced a non-
significant decrease of ET-1 concentration, which may be
important for the therapeutic use of amlodipine in every-
day practice. However, it should be also noted that our
data were collected from a relatively small group of pa-
tients (39), and probably need to be confirmed in larger
population sample.
key words: endothelin-1, amlodipine, essential
hypertension, calcium antagonists
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